HS 292146 Amfetamine (INN), benzfetamine (INN), dexamfetamine (INN), etilamfetamine (INN), fencamfamin (INN), lefetamine (INN), levamfetamine (INN), mefenorex (INN) and phentermine (INN); salts thereof
Quick Answer: HS code 2921.46 specifically covers a group of controlled stimulant drugs, including Amfetamine, Benzfetamine, Dexamfetamine, and Phentermine, along with their respective salts. These are primarily pharmaceutical raw materials or bulk active pharmaceutical ingredients (APIs) used in regulated medical applications. For importers and exporters, understanding the highly restrictive nature of these substances is paramount. While the UK and EU tariffs show a 0.00% ad valorem duty rate, the US imposes a complex duty of "Free, 15.4¢/kg + 149.5%". The "Free" rate typically applies to products meeting specific conditions, often related to end-use or specific trade programs. Beyond duties, these products are subject to stringent import/export licensing, quotas, and regulatory controls by national drug enforcement agencies (e.g., DEA in the US, MHRA in the UK, EMA in the EU) due to their potential for abuse and diversion. Customs brokers must ensure all necessary permits and declarations are in place before shipment.
What Are the Import Duty Rates?
🇬🇧 United Kingdom
| Code | MFN | Preferential | Unit |
|---|---|---|---|
| 2921460000 | 0.00 % | — | — |
🇪🇺 European Union (TARIC)
| Code | MFN | Preferential | Unit |
|---|---|---|---|
| 2921460000 | 0.00 % | — | — |
🇺🇸 United States (HTSUS)
| Code | MFN | Preferential | Unit |
|---|---|---|---|
| 2921460000 | Free | — | ["kg"] |
Duty rates sourced from the USITC (US International Trade Commission) Harmonized Tariff Schedule (HTS) (accessed 2/22/2026), EU TARIC – DG TAXUD (Directorate-General for Taxation and Customs Union) (accessed 2/22/2026), and UK Trade Tariff – HMRC (His Majesty's Revenue and Customs) (accessed 2/22/2026).
Data compiled and presented by HSRates.
How to Classify This HS Code?
What products does HS 292146 cover?
This subheading covers a specific group of acyclic monoamines and their derivatives, specifically Amfetamine (INN), Benzfetamine (INN), Dexamfetamine (INN), Etilamfetamine (INN), Fencamfamin (INN), Lefetamine (INN), Levamfetamine (INN), Mefenorex (INN), and Phentermine (INN), as well as their respective salts. The "INN" designation refers to International Nonproprietary Names, which are globally recognized generic names for pharmaceutical substances. This classification is precisely defined by the Harmonized System Nomenclature, as published by the World Customs Organization (WCO), and is consistently applied in national tariffs such as the USITC Harmonized Tariff Schedule (HTS) and the EU TARIC system, ensuring uniform identification of these controlled substances for trade and regulatory purposes.
What falls outside HS 292146?
The following products are excluded from HS 292146, even if they share structural similarities or therapeutic uses. For instance, other acyclic monoamines not specifically listed in the subheading, such as ephedrine or pseudoephedrine, are classified elsewhere, typically under HS 2939 for alkaloids. Similarly, complex derivatives or preparations containing these substances in mixtures or dosage forms are generally excluded from this pure chemical subheading. Preparations of these substances for therapeutic or prophylactic uses, for example, would fall under Chapter 30, specifically heading 3004, if they are medicaments consisting of mixed or unmixed products for such uses, rather than the pure chemical compounds themselves.
What are common classification mistakes for HS 292146?
A common error is misclassifying pharmaceutical preparations containing the listed substances under HS 292146, rather than under Chapter 30. This subheading is strictly for the pure chemical compounds and their salts, not for finished medicaments or dosage forms. Importers sometimes overlook General Interpretative Rule (GRI) 3(b), which prioritizes classification by essential character for mixtures, or GRI 3(a) which addresses the most specific description. Another mistake involves incorrectly classifying isomers or derivatives not explicitly named in the subheading, assuming structural similarity is sufficient for inclusion. Each listed substance is an "INN," meaning its exact chemical structure and name are internationally recognized and must be precisely matched.
How should importers classify products under HS 292146?
The correct procedure for classifying products under HS 292146 requires meticulous attention to the chemical identity of the substance. Importers and customs brokers must first verify that the product is one of the nine specific INN-designated compounds (Amfetamine, Benzfetamine, Dexamfetamine, Etilamfetamine, Fencamfamin, Lefetamine, Levamfetamine, Mefenorex, or Phentermine) or a salt thereof. This verification should be supported by a Certificate of Analysis (CoA) or other authoritative chemical documentation. Furthermore, it is crucial to ensure the product is in its pure chemical form, not a pharmaceutical preparation or mixture, which would typically fall under Chapter 30. Consulting the WCO Explanatory Notes for Heading 2921 and cross-referencing with the USITC HTS or EU TARIC system for specific national duty rates, such as the 6.5% ad valorem rate for many chemicals in this chapter in the US, is essential for accurate declaration and compliance.
Which HS Codes Are Related?
Not the right code? Search all HS codes to find the correct tariff classification.
FAQ
What are the Most Favored Nation (MFN) duty rates for products classified under HS 2921.46?
The MFN duty rates for products under HS 2921.46, which includes specified amphetamine-type stimulants and their salts, are typically 0.00% ad valorem in many major trading blocs, reflecting their nature as pharmaceutical intermediates or controlled substances. For example, the Harmonized Tariff Schedule of the United States (HTSUS) generally lists a 'Free' rate for Column 1 (MFN) for this subheading. Similarly, the EU TARIC database often shows a 0.00% ad valorem duty. Importers should always verify the specific duty rate applicable to their country of import via the official tariff schedule (e.g., USITC HTSUS, EU TARIC, UK Trade Tariff).
Are there any preferential duty rates available for HS 2921.46 under common trade agreements?
Given the nature of the substances classified under HS 2921.46, preferential duty rates are often 'Free' or 0.00% ad valorem if the MFN rate is already zero. However, eligibility for preferential treatment under trade agreements such as the USMCA (United States-Mexico-Canada Agreement), GSP (Generalized System of Preferences), or various Free Trade Agreements (FTAs) would still require meeting the specific Rules of Origin criteria of the respective agreement. For example, a product originating in a USMCA country would typically enter the U.S. duty-free under the USMCA if it meets the origin requirements, even if the MFN rate is already free. Importers should consult the specific trade agreement's origin rules and provide the necessary documentation (e.g., certificate of origin) to claim preferential treatment.
What are the key classification criteria for substances under HS 2921.46?
Classification under HS 2921.46 is highly specific, covering 'Amfetamine (INN), benzfetamine (INN), dexamfetamine (INN), etilamfetamine (INN), fencamfamin (INN), lefetamine (INN), levamfetamine (INN), mefenorex (INN) and phentermine (INN); salts thereof'. The primary criterion is the precise chemical identity of the substance, which must match one of the listed International Nonproprietary Names (INN) or be a salt of one of those compounds. Importers must ensure that the chemical name, CAS number, and molecular structure of their product precisely correspond to one of these specified amphetamine-type stimulants. Purity levels and the presence of isomers (e.g., dextro- or levo- forms) are critical for accurate classification. WCO Explanatory Notes for Chapter 29 provide further guidance on the classification of organic chemicals and their derivatives.
What specific documentation and regulatory requirements apply to the importation of HS 2921.46 substances?
Importation of substances under HS 2921.46 is subject to stringent controls due to their classification as controlled substances. In addition to standard customs documentation (commercial invoice, packing list, bill of lading/air waybill), importers will require specific permits and licenses from national drug enforcement or regulatory agencies. For instance, in the United States, this would involve compliance with the Drug Enforcement Administration (DEA) regulations, including DEA Form 236 (Application for Permit to Import Controlled Substances) and DEA Form 357 (Declaration for Importation of Controlled Substances). Similar controls exist in the EU (e.g., national competent authorities under EU regulations for precursors and controlled substances) and the UK (e.g., Home Office licensing). A Certificate of Analysis (CoA) is crucial to verify the chemical identity and purity. Importers must ensure all national and international conventions (e.g., UN Conventions on Psychotropic Substances) are adhered to, and that the end-use is legitimate and authorized.
Are there any anti-dumping or countervailing duties (AD/CVD) that could apply to HS 2921.46?
While the MFN duty rates for HS 2921.46 are typically 0.00% or 'Free', anti-dumping (AD) and countervailing duties (CVD) are separate and can be imposed irrespective of the standard duty rate. AD/CVD are product- and country-specific, designed to offset unfair pricing or subsidies. For substances under HS 2921.46, the likelihood of AD/CVD being in place is generally lower compared to high-volume industrial chemicals or consumer goods, given their specialized nature and strict regulatory controls. However, importers must always check the latest trade remedies databases of the importing country (e.g., U.S. Department of Commerce, EU Commission Trade Defence website, UK Trade Remedies Authority) to determine if any active AD/CVD orders apply to the specific product and country of origin at the time of importation. Failure to account for applicable AD/CVD can result in significant penalties.